Biological agents for ulcerative colitis: Hypes and hopes

✍ Scribed by Silvio Danese; Erika Angelucci; Alberto Malesci; Renzo Caprilli

• Book ID: 102507203
• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 232 KB
• Volume: 28
• Category: Article
• ISSN: 0198-6325
• DOI: 10.1002/med.20103

✦ Synopsis

Abstract

Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colonic mucosa. Over the last decade, the increasing knowledge on the pathogenic mechanisms underlying intestinal inflammation has led to the development of a number of biological agents, mainly addressed to molecules and/or pathways demonstrated to have a pathogenic role in UC. In UC, clinical course and therapeutic decisions mainly depend on disease activity and extent. While therapeutic approach to mild‐to‐moderate UC by using aminosalicylates and corticosteroids has been well established, treatment of severe UC is far from being satisfactory. A severe attack of UC remains a challenge to be managed jointly by gastroenterology, surgery, and intensive care units. However, the recent introduction of biological therapies has led to promising changes in the management of UC patients. Aim of this paper is to review the recent advances and future perspectives for the use of biological agents in UC. © 2007 Wiley Periodicals, Inc. Med Res Rev, 28, No. 2, 201–218, 2008